A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects
DOI: https://doi.org/10.2147/ITT.S370435
2022-09-28
ImmunoTargets and Therapy
Abstract:Muhammet Celik, 1 Brian Fuehrlein 2, 3 1 Research Division, VA Connecticut Healthcare System, West Haven, CT, USA; 2 Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; 3 Mental Health Service Line, VA Connecticut Healthcare System, West Haven, CT, USA Correspondence: Brian Fuehrlein, Mental Health Service Line, VA Connecticut Healthcare System, 950 Campbell Ave, West Haven, CT, 06516, Tel +1-203-932-5711 x4471, Fax +1-203-937-4904, Email Substance use disorders (SUDs) have been a major public health challenge for decades and continue to cause significant morbidity and mortality worldwide. Due to limitations in pharmacologic treatment options, there remains a significant need for the development of novel immunotherapeutic approaches. In this review, we discuss the therapeutic potential of vaccines for SUDs. Although early preclinical animal studies were optimistic and successful, few vaccines have reached human clinical trials. Only nicotine and cocaine vaccines have successfully advanced to Phase 3 clinical trials and neither are currently available as a treatment option. Various innovative approaches in vaccine design have been made to overcome limitations and improve immunogenicity, including the use of nanoparticles, synthetic haptens, and more immunogenic adjuvants. While success has thus far been elusive, with substantial scientific advancements in vaccine technology, immunotherapy remains a promising and viable option for the treatment of SUDs. Keywords: substance use disorder, vaccines, nicotine, opioid, cocaine, methamphetamine Two centuries have passed since Edward Jenner first inoculated an 8-year-old boy with cowpox using active pustules from a cowpox patient on May 14, 1796, 1 and scientific advances in immunotherapeutic approaches continue. With the most recent humanitarian disaster, the COVID-19 pandemic, the importance of vaccines was highlighted once again. Substance use disorders (SUDs) are characterized by a clinically significant impairment in health and social function and loss of control over use despite adverse consequences. 2 SUDs are a rapidly growing public health concern worldwide. Based on data from the National Survey on Drug Use and Health (NSDUH), approximately 14.5% of individuals 12 years or older in the US met criteria for a SUD. 3 Based on data from the 2021 world drug report, 36 million people worldwide were affected by drug use disorders in 2019—an increase of 9 million from the estimate in 2010. Despite this increase, the availability of treatment options is limited. 4 Could vaccines play a role? The first use of drug-specific antibodies as a therapeutic agent was in an animal study in the 1970s which consisted of using a morphine–bovine serum albumin (BSA) conjugate to attenuate heroin self-administration in a rhesus monkey. 5 Current immunotherapeutic approaches for SUDs mainly include active immunization with vaccines, anti-drug monoclonal antibodies (mAb), catalytically efficient metabolic enzymes, and gene transfer of anti-drug proteins, including mAb. 6 Vaccines are able to generate high-affinity anti-drug IgG antibodies that neutralize and prevent the drug from acting on its receptor sites in the brain. 6 Conjugate vaccines have been shown to be effective in producing promising physiological and behavioral results in pre-clinical and clinical studies. 6 In the production of the anti-drug vaccine, a chemical linker is being used to generate a hapten. 7 This is primarily due to the small molecule drugs' inability to create immunogenicity. Coupling the hapten with a carrier protein produces a drug immunoconjugate preserving the chemical structure of the drug. With the formulation of the immunoconjugate with adjuvants, the anti-drug vaccine production ends. 7 Due to its ability to induce T-helper (Th)2-type immunity, which favors drug-neutralizing IgG antibody production as a result of CD4 T cell dependent B cell activation and cost-effectiveness, alum is considered an ideal adjuvant. 7,8 Moreover, to target innate immunity, molecules called pathogen-associated molecular patterns (PAMPs) are added to alum to target innate immune receptors and increase the vaccine's immunogenicity. 7 PAMPs can be found in infectious bacteria and viruses and activate pattern recognition receptors (PRRs) to stimulate D.C. and B cell maturation. 9 Among several distinct classes of PRRs, toll-like receptors (TLRs) are widely targeted as they induce a long-lasting immune response. 7,9 Currently, the only FDA-approved TLR adjuvant is Monophosphoryl lipid A (MPLA), a clinically utilized TLR-4 agonist. 9 As a successful example, addition of TLR9 (CpG ODN 1826 -Abstract Truncated-